BD US Government Partnership Commits $19 Billion to US Manufacturing

The BD US government partnership, announced on 6 October 2026, commits the medical technology company to a $19 billion investment in American manufacturing over several years. In return, BD receives relief from future tariffs on covered products. BD (Becton, Dickinson and Company) is the largest US manufacturer of essential medical consumables. These single-use supplies are used by clinicians and patients every day and appear in approximately 90% of US hospital visits.

The company, based in Franklin Lakes, New Jersey, said the agreement supports investment in domestic manufacturing, innovation and end-to-end production capability. The deal fits the Trump administration’s push to expand domestic manufacturing capacity and secure the supply chain for products critical to patient care and healthcare preparedness.

What BD has committed to

Through the partnership, BD intends to:

Ad

• Invest $19 billion in the United States over several years, including capital, operational and supply chain investments.
• Direct $3 billion of that total toward US manufacturing expansion, focused on strategic production sites across the country.
• Expand annual US output of essential medical consumables by approximately 5 billion units, raising BD’s share of domestically supplied essential consumables to roughly 80 percent.
• Manufacture 100 percent of the needles BD uses in America domestically, from American-made steel.

Tariff relief tied to milestones

The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs. That relief is subject to the final scope and implementation of any future Section 232 actions, and to BD reaching agreed milestones. For the company, the provision offers greater certainty for manufacturing and supply chain planning as it advances investment in US production and healthcare infrastructure.

Because the final tariff rates, product scope and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement. The company expects to provide additional information once the Section 232 tariffs are settled.

Where BD makes essential consumables in the US

BD’s US manufacturing network runs through communities including Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina.

The company’s domestic manufacturing history goes back nearly 130 years. It developed the first disposable syringe, which helped advance the fight against polio, and delivered more than two billion additional devices during the recent pandemic.

Industry context for the BD US government partnership

BD is not alone in reworking its production footprint around US policy. Manufacturers and payers have spent the past two years responding to trade measures aimed at bringing medicine production back on shore, from the US pharmaceutical supply chain reserve to proposals for reshoring essential medicines production and reshoring generic drug production under phased tariffs.

What distinguishes BD’s agreement is its scale relative to the product category. The company supplies high-volume consumables rather than patented medicines, so the $19 billion commitment and the 5 billion unit capacity increase land on the everyday items that hospitals cannot substitute quickly when supply fails.

Collectively, BD says these commitments will help establish one of the world’s most resilient essential medical consumables manufacturing bases and strengthen America’s healthcare resilience for future generations.

What BD’s leadership says

Tom Polen, chairman, CEO and president of BD, framed the agreement as a shared undertaking. “This agreement reflects a shared commitment between the U.S. Government and BD to strengthening America’s healthcare infrastructure, expanding U.S. manufacturing capacity and supporting reliable access to essential medical technologies, ultimately building a more resilient healthcare system for the future,” he said.

Polen added that the administration recognizes the value of investing in a more secure healthcare supply chain. “The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and BD is uniquely positioned to help bring that vision to life through our scale, innovation expertise and longstanding U.S. manufacturing footprint,” he said.

He also tied the agreement to the company’s longer history in the market. “For nearly 130 years, BD has partnered with health systems and governments in the U.S. and around the world to meet critical healthcare challenges,” he said.

Source: BD and U.S. Government Launch Landmark Partnership, PR Newswire, 6 October 2026